Law360, New York (October 23, 2008) -- The Hatch-Waxman Act has led to an explosion of antitrust cases in the pharmaceutical industry, which is expected to fuel the next wave of antitrust cases, according to attorneys from Dechert LLP’s antitrust practice.
George G. Gordon, co-head of the practice, said work involving efforts by branded pharmaceutical companies to enforce intellectual property rights against generic competitors has constituted one of the largest growth...
